Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS.
Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH. Gross JA, et al. Among authors: mudri s. Immunity. 2001 Aug;15(2):289-302. doi: 10.1016/s1074-7613(01)00183-2. Immunity. 2001. PMID: 11520463 Free article.
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease.
Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH. Gross JA, et al. Among authors: mudri s. Nature. 2000 Apr 27;404(6781):995-9. doi: 10.1038/35010115. Nature. 2000. PMID: 10801128
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.
Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, Schrader S, Burkhead S, Heipel M, Brandt C, Kuijper JL, Kramer J, Conklin D, Presnell SR, Berry J, Shiota F, Bort S, Hambly K, Mudri S, Clegg C, Moore M, Grant FJ, Lofton-Day C, Gilbert T, Rayond F, Ching A, Yao L, Smith D, Webster P, Whitmore T, Maurer M, Kaushansky K, Holly RD, Foster D. Parrish-Novak J, et al. Among authors: mudri s. Nature. 2000 Nov 2;408(6808):57-63. doi: 10.1038/35040504. Nature. 2000. PMID: 11081504
Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.
Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, Haugen HS, Maurer M, Harder B, Johnston J, Bort S, Mudri S, Kuijper JL, Bukowski T, Shea P, Dong DL, Dasovich M, Grant FJ, Lockwood L, Levin SD, LeCiel C, Waggie K, Day H, Topouzis S, Kramer J, Kuestner R, Chen Z, Foster D, Parrish-Novak J, Gross JA. Dillon SR, et al. Among authors: mudri s. Nat Immunol. 2004 Jul;5(7):752-60. doi: 10.1038/ni1084. Epub 2004 Jun 6. Nat Immunol. 2004. PMID: 15184896
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, Ardourel D, Wolfson MF, Debrot S, Mudri S, Kleist K, Griffin LL, Hebb L, Sanderson RJ, Wang N, Seaberg M, Chunyk AG, Yang J, Hong Y, Maria Z, Messenheimer DJ, Holland PM, Peng SL, Rixon MW, Dillon SR. Evans LS, et al. Among authors: mudri s. Arthritis Rheumatol. 2023 Jul;75(7):1187-1202. doi: 10.1002/art.42462. Epub 2023 Apr 19. Arthritis Rheumatol. 2023. PMID: 36705554
Non-Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101).
Dillon SR, Evans LS, Lewis KE, Debrot S, Blair TC, Mudri S, Kleist K, Levin SD, Bhandari JG, Garrett L, Wolfson MF, Holland PM, Rixon MW, Peng SL. Dillon SR, et al. Among authors: mudri s. Arthritis Rheumatol. 2023 Aug;75(8):1344-1356. doi: 10.1002/art.42484. Epub 2023 May 9. Arthritis Rheumatol. 2023. PMID: 36862144
ICOSL+ plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist.
Adom D, Dillon SR, Yang J, Liu H, Ramadan A, Kushekhar K, Hund S, Albright A, Kirksey M, Adeniyan T, Lewis KE, Evans L, Wu R, Levin SD, Mudri S, Yang J, Rickel E, Seaberg M, Henderson K, Gudgeon CJ, Wolfson MF, Swanson RM, Swiderek KM, Peng SL, Hippen KL, Blazar BR, Paczesny S. Adom D, et al. Among authors: mudri s. Sci Transl Med. 2020 Oct 7;12(564):eaay4799. doi: 10.1126/scitranslmed.aay4799. Sci Transl Med. 2020. PMID: 33028709 Free PMC article.
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Maurer MF, Lewis KE, Kuijper JL, Ardourel D, Gudgeon CJ, Chandrasekaran S, Mudri SL, Kleist KN, Navas C, Wolfson MF, Rixon MW, Swanson R, Dillon SR, Levin SD, Kimbung YR, Akutsu M, Logan DT, Walse B, Swiderek KM, Peng SL. Maurer MF, et al. Among authors: mudri sl. Nat Commun. 2022 Apr 4;13(1):1790. doi: 10.1038/s41467-022-29286-5. Nat Commun. 2022. PMID: 35379805 Free PMC article.
15 results